Last reviewed · How we verify
MECAMYLAMINE HYDROCHLORIDE
At a glance
| Generic name | MECAMYLAMINE HYDROCHLORIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1956 |
Approved indications
- Moderate to severe essential hypertension
- Uncomplicated malignant hypertension
Common side effects
- Constipation
- Nausea
- Vomiting
- Orthostatic dizziness
- Postural hypotension
- Weakness
- Fatigue
- Blurred vision
- Anorexia
- Dryness of mouth
- Sedation
- Urinary retention
Serious adverse events
- Ileus
- Syncope
- Convulsions
- Choreiform movements
- Mental aberrations
- Interstitial pulmonary edema
- Interstitial pulmonary fibrosis
Drug interactions
- antibiotics and sulfonamides
- anesthesia
- other antihypertensive drugs
- alcohol
Key clinical trials
- Cholinergic Health After Menopause (CHAMP) (EARLY_PHASE1)
- Treatment of Orthostatic Intolerance (PHASE1, PHASE2)
- Cholinergic Mechanisms of Attention in Aging (EARLY_PHASE1)
- Attentional Mechanisms in SCD (EARLY_PHASE1)
- The Nicotinic Cholinergic System and Cognitive Aging (PHASE1)
- Mecamylamine for Autonomic Dysreflexia Prophylaxis (PHASE4)
- Nicotinic Modulation of the Default Network (NA)
- Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MECAMYLAMINE HYDROCHLORIDE CI brief — competitive landscape report
- MECAMYLAMINE HYDROCHLORIDE updates RSS · CI watch RSS